Exclusive Agreement Announced Between Quidel Corporation and Roche Pharma AG

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, announced today an exclusive partnership to provide Roche Pharma AG with the QuickVue Influenza A+B rapid diagnostic test for its marketing and selling activities along with its Tamiflu (Oseltamivir) antiviral for the 2007 – 2008 influenza season in Germany. The agreement will leverage the strength and speed of the QuickVue rapid test to help characterize influenza infection (the flu) along with the Tamiflu treatment to improve patient recovery time.